Law Change Would Help Kolon As It Progresses Pipeline
This article was originally published in PharmAsia News
Executive Summary
Kolon life Science expects South Korea’s government to ease gene therapy rules to help the company launch its osteoarthritis drug in the domestic market, and is looking to complete licensing talks with potential global partners before the product's launch, the venture said at a recent investors’ meeting.